The earnings call highlighted strong financial and operational performance, including record revenue growth and successful strategic expansions in key market segments such as Scoliosis and OPSB. However, there were challenges such as a decline in gross margin, slower than expected T&D growth, and restructuring charges. Overall, the positive aspects of the company's performance and future outlook significantly outweigh the negatives.

Company Guidance

During the OrthoPediatrics Corporation's second quarter 2025 earnings call, several key performance metrics and strategic initiatives were highlighted. The company achieved record revenue with a global growth rate of 16%, treating over 37,000 children in the quarter and over 1,217,000 since inception. Notably, the Scoliosis business grew by 35%, driven by increased demand in the U.S. and international markets. The Trauma and Deformity (T&D) segment expanded by 10%, despite slower set sales in Latin America. OrthoPediatrics raised its full-year revenue guidance from $236-242 million to $237-242 million and maintained an adjusted EBITDA expectation of $15-17 million, with the company anticipating its first positive free cash flow in Q4 2025. The Non-Surgical Specialty Bracing (OPSB) business grew over 20%, with significant clinic expansions, including new openings in California and Denver, as well as the first international clinic in Ireland. The company is also on track with its product development, having recently received FDA approval for sterile products and planning further innovations within its 3P Pediatric Plating Platform and EOS product portfolio.

Record-Breaking Revenue Growth

OrthoPediatrics reported record revenue with a global growth of 16% for Q2 2025, driven by market share gains across all businesses, including standout performances in Scoliosis, Trauma, and OPSB.

Strong Scoliosis Business Performance

The Scoliosis business saw a significant 35% growth in Q2 2025, driven by new surgeon adoption and increased demand in both U.S. and international markets.

OPSB Expansion Success

OPSB achieved growth exceeding 20% and surpassed initial 2025 territory expansion goals, with new clinics opened in major markets such as New York City and California.

Positive Adjusted EBITDA and Cash Flow Outlook

OrthoPediatrics reported a 50% improvement in adjusted EBITDA, with a projection to achieve positive free cash flow in Q4 2025 and full-year breakeven in 2026.

International Market Expansion

International sales increased by 12%, driven by strong surgical demand in Europe and scoliosis set sales, despite some challenges in Latin America.

OrthoPediatrics (KIDS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KIDS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.25 / -	-0.18	―	―	―
Aug 05, 2025	2025 (Q2)	-0.29 / -0.11	-0.23	52.17% (+0.12)
May 07, 2025	2025 (Q1)	-0.44 / -0.39	-0.3	-30.00% (-0.09)	―
Mar 04, 2025	2024 (Q4)	-0.30 / -0.29	-0.23	-26.09% (-0.06)	―
Nov 06, 2024	2024 (Q3)	-0.23 / -0.18	-0.13	-38.46% (-0.05)	―
Aug 05, 2024	2024 (Q2)	-0.26 / -0.23	-0.19	-21.05% (-0.04)	―
May 06, 2024	2024 (Q1)	-0.41 / -0.30	-0.29	-3.45% (-0.01)	―
Mar 06, 2024	2023 (Q4)	-0.27 / -0.23	-0.32	28.13% (+0.09)	―
Nov 06, 2023	2023 (Q3)	-0.21 / -0.13	-0.05	-160.00% (-0.08)	―
Jul 31, 2023	2023 (Q2)	-0.20 / -0.19	-0.17	-11.76% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KIDS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$20.19	$17.90	-11.34%
May 07, 2025	$22.18	$23.08	+4.06%
Mar 04, 2025	$22.89	$25.61	+11.88%
Nov 06, 2024	$30.95	$27.49	-11.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does OrthoPediatrics Corp (KIDS) report earnings?

OrthoPediatrics Corp (KIDS) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is OrthoPediatrics Corp (KIDS) earnings time?

OrthoPediatrics Corp (KIDS) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KIDS EPS forecast?

KIDS EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing